<DOC>
	<DOCNO>NCT00683878</DOCNO>
	<brief_summary>The purpose clinical research study learn BMS-512148 ( Dapagliflozin ) help reduce blood sugar level subject Type 2 Diabetes well control TZD alone . The safety treatment also study</brief_summary>
	<brief_title>Add-on Thiazolidinedione ( TZD ) Failures</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>2,4-thiazolidinedione</mesh_term>
	<criteria>Males female , ≥ 18 year old , type 2 diabetes inadequate glycemic control All subject must central laboratory prerandomization A1C ≥ 7.0 ≤ 10.5 % Cpeptide ≥ 1.0 ng/mL ( 0.34 nmol/L ) Body Mass Index ≤ 45.0 kg/m² AST /or ALT &gt; 2.5 time upper limit normal Serum total bilirubin &gt; 2 mg/dL ( 34.2 µmol/L ) Creatinine kinase &gt; 3.0 time upper limit normal Symptoms severely uncontrolled diabetes Serum creatinine ≥ 2.0 mg/dL Calculated CrClearance &lt; 50 ml/min ( calculate CockroftGault formula ) Currently unstable serious cardiovascular , renal , hepatic , hematological , oncological , endocrine , psychiatric , rheumatic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>